Related Experiment Video

Updated: Jun 11, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

MicroRNA-1307-3p contributes to breast cancer progression through PRM2

José Roberto Estupiñan-Jiménez1, Valeria Villarreal-García1, Vianey Gonzalez-Villasana1

  • 1Departmento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.

Thoracic Cancer
|October 9, 2024
PubMed
Abstract

Insights

MicroRNA miR-1307-3p promotes breast cancer (BC) growth and spread. Inhibiting this microRNA and targeting its novel gene, protamine 2 (PRM2), may offer new therapeutic strategies for BC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer (BC) remains a leading global cancer in women.
  • MicroRNA (miRNA) dysregulation is implicated in BC development.
  • miR-1307-3p is upregulated in BC, but its functions and targets are not fully understood.

Purpose of the Study:

  • To investigate the role of miR-1307-3p in BC cell proliferation, migration, invasion, and angiogenesis.
  • To identify and validate target genes of miR-1307-3p in BC.

Main Methods:

  • Quantitative real-time reverse transcription-PCR (RT-qPCR) to measure miR-1307-3p levels.
  • Assessment of BC cell behavior following miR-1307-3p inhibition.
  • Bioinformatic analysis and experimental validation (Western blot, dual-luciferase assays) to identify and confirm miR-1307-3p targets.

Main Results:

  • Inhibition of miR-1307-3p significantly suppressed BC cell proliferation, migration, invasion, and angiogenesis.
  • Bioinformatics predicted 17 potential targets for miR-1307-3p.
  • Protamine 2 (PRM2) was confirmed as a direct target gene of miR-1307-3p.

Conclusions:

  • Overexpression of miR-1307-3p drives key hallmarks of breast cancer progression.
  • PRM2 is identified as a novel target of miR-1307-3p in the context of breast cancer.
  • Targeting miR-1307-3p and its downstream effectors like PRM2 may represent a therapeutic avenue for BC.
Keywords:
breast cancercancer progressionmiR‐1307‐3pmicroRNAsprotamine 2

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.2K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.5K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K